drugset / Trial / NCT00133731
The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention
RandomizedParallel-groupDouble-blindTreatment
Summary
The objective of this dose-ranging study is to determine the effects of several intravenous (IV) regimens of otamixaban on pharmacodynamic markers (including markers of thrombosis and coagulation markers), safety/tolerability, clinical efficacy and pharmacokinetics.
Timeline
- Start
- 2004-09
- Primary completion
- —
- Completion
- 2005-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HEPARIN CALCIUM | Other / unclassified | — | Intravenous |
| Subject | Otamixaban | Small molecule | — | Intravenous |
Indications
No indication recorded.